The marijuana sector is still a volatile market, but with California now "fully legal" and Canada headed that way this summer, there are billions on the table; far too much upside for any investor to ignore.
But with such a massive amount of profit potential, it's all too easy for investors to be tempted by the hype and take the "high-risk" route.
That's why the "conservative-aggressive" approach is the one I recommend for getting started: Target low-risk companies – blue chips, in many cases – that are enabling the broader pot stock sector to flourish.
These easy-to-own companies are the best way to get started on the road to "marijuana millions." They're the perfect base on which to build a legal cannabis portfolio.
Pick No. 1: GW Pharmaceuticals Plc.
I recommended this stock way back in March 2014, and even back then, it was a leader in biotechnology. I still consider it to be one of the best cannabis tech plays available today.
Founded in 1998, GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH) is the global leader in the development of plant-based cannabinoid therapeutics. The company is partnering with a couple of the world's largest publicly traded drug firms and stands to gain more than $300 million in revenue from those alliances alone.
Pot Stock Profits: A historic event is unfolding in California's marijuana markets, and the wealth expected to flow into this industry is record-breaking. Learn how to cash in here…
And better yet, it is a big play on the cannabis industry because of the company's robust pipeline, which includes several drugs that utilize the science behind cannabinoids.
GW Pharmaceuticals is focused on the huge potential behind the more than 65 types of these cannabinoid compounds already discovered.
The two most abundant are tetrahydrocannabinol (THC) and cannabidiol (CBD). GW Pharmaceuticals uses both, but in very different ways.
Fact is, the company's main product candidate, Sativex, has awesome potential to treat patients with pain from cancer as well as those with a condition known as MS spasticity, which results in muscle spasms and stiffness associated with the diseases multiple sclerosis.
Sativex treats these conditions by allowing THC, CBD, and a naturally occurring chemical called anandamide to bind to receptors in the brain.
Meantime, GW Pharmaceuticals is also teaming with some heavy hitters in the pharmaceutical industry to help fund the development of Sativex.
The rest of the company's pipeline also shows great promise.
It has a product candidate called Epidiolex to treat rare types of epilepsy in children. The key here is that GW's compound actively negates the euphoric and cognitive effects of THC when administered to children.
Epidiolex is proposed to treat conditions that are estimated to afflict around 95,000 cases in the United States and some 150,000 more in Europe, including children with Dravet syndrome, a rare form of infant epilepsy.
Some of GW Pharmaceuticals' additional candidates aim to treat type 2 diabetes and schizophrenia and have already entered phase 2 trials.
With a $2.9 billion market cap, the stock trades at roughly $111.57 a share, up more than 54% over the years.
With its solid science, multiple uses for its main cannabis-based biotech product, and strong alliances with global drug leaders, GW Pharmaceuticals should leave investors richly rewarded.
Pick No. 2: Microsoft Corp.
I recommended Microsoft Corp. (Nasdaq: MSFT) as a pot play in August 2017 because many pot entrepreneurs lack the knowledge and experience necessary to comply with all state and local regulations, from employment and labor laws, to inventory control, and everything in between.
With a market likely to top $35 billion in three years, the stakes are just too high to leave anything to chance.
Entrepreneurs are turning in droves to the one company that can make it all easy for them…
That's why I love Microsoft Corp. (Nasdaq: MSFT) in this space.
Microsoft has marketed its cloud-based services heavily to players in the sector, and it's beginning to pay off.
Here's where California's recreational weed market comes in. Now, its medical marijuana market alone accounts for some 33% of all legal sales in the United States.
Conservative estimates suggest California's new market will be worth $1.57 billion in the first year after legalization, before it triples by the early 2020s.
And all the state's vendors are going to need the product that Microsoft is laser-focused on right now.
This is a huge profit catalyst for "Mr. Softy" that really makes the case for owning it now.
While Microsoft has yet to match Amazon dollar for dollar in this fast-growing tech segment, its recent track record has gotten Wall Street's attention.
That means now is the time to "Accumulate" a bigger position. I think the near 30% in gains Microsoft has given us in the meantime are just the start.
Pick No. 3 Scotts Miracle-Gro Co.
This last "safe" weed play was recommended in September 2017, and the reason should be pretty clear.
Every pot grower knows lots of care, technique, and, of course, technology goes into the cultivation and feeding of marijuana plants so they can flower and produce a whole host of commercially and medically useful compounds – especially the psychoactive tetrahydrocannabinol-9 (THC) that gets users high.
This is seriously labor- and tech-intensive stuff. It's also the specialty of Scotts Miracle-Gro Co. (NYSE: SMG).
While the legalization of marijuana is creating the need for acres and acres of professionally grown cannabis, you shouldn't forget the little guys. After all, for decades thousands of consumers have been growing their own, even while risking trouble with law enforcement. By one estimate, $60 billion worth of illegal pot is grown each year in the United States.
But with marijuana now legal in 29 states and counting, the number of people looking to cultivate it for their own consumption is likely to skyrocket.
The marijuana-growing market could easily top $100 billion within five years, with much of that supply displacing imported marijuana from dangerous jungles in Latin America.
And while this opens up an opportunity for firms that cater to growers and gardeners, it also presents those firms with a strategic dilemma. Should they establish a strong early presence in the pot-growing community? Or wait until the social climate around cannabis normalizes – that is, until growing your own pot is no more controversial than brewing your own beer?
Scotts is going with the first option: embrace this fast-growing community of growers and, by doing so, "plant the seeds" for robust new paths to growth.
Scotts is already the world's largest maker of lawn care and gardening products and is now making a big push into indoor plant cultivation, as evidenced by its April 2015 purchase of General Hydroponics.
This method means no mess and, more importantly, no pesticides. That's a key consideration for green consumers.
Now, given the admittedly unsettled legal landscape around cannabis, Scotts' emphasis on that market might seem like a dangerous choice.
But in truth, it's less risky than it seems.
If the legal marijuana movement stalls, Scotts will still benefit from the growing demand for hydroponic equipment among young urban consumers eager to grow the herbs and greens that go into their salads.
But it's hard to imagine the push for legal marijuana stalling out. In many respects, that genie has left the bottle.
Even before legal pot made this new growth potential possible, hydroponics had been very popular with a whole array of growers.
According to Manifest Minds LLC, the global crop value of hydroponically grown plants is on pace to rise from $17 billion in 2013 to $24 billion by 2018.
If other countries follow the lead set by the United States, pot cultivation – and hydroponics – could well soar much higher than that.
Additionally, Scotts' four leading brands (Scotts, Miracle-Gro, Roundup, and Ortho) have a commanding position, with market shares ranging from 53% to 70%.
And the firm is out to make it easy for people to start using hydroponics equipment to grow either cannabis or food. Scotts Miracle-Gro has 2,500 sales associates that it sends to visit retail stores after training them on the merits of hydroponics.
Make no mistake: This is not your typical cannabis investment. For one thing, Scotts is already quite popular with mutual fund managers, who like the fact that the firm has boosted its dividend for seven straight years. It's given us peak gains of more than 13%, and I see its recent retreat as an opportunity to buy more and build an even bigger position.
Look, building a well-rounded cannabis portfolio is absolutely essential for unlocking massive profit potential with balanced risk.
Scotts is the clear choice to anchor the low-risk end of the spectrum. And its early move to embrace the cannabis community could help turn it into a robust grower.
These Tiny Pot Stocks Could Skyrocket: In a recent interview, marijuana stocks expert Michael Robinson shared his insight on California's total cannabis legalization and delivered details on the huge gains you could have the chance to enjoy. Get the top three marijuana stocks he's watching now – and learn how to position yourself to profit – by clicking here.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.